مکتبة رقمیه للعلوم الطبيه
Your cart is empty.
  • Cart
  • Lists
    Your lists Log in to create your own lists
  • Log in to your account
  • Your cookies
  • Search history
  • Advanced search
  • Authority search
  • Tag cloud
  • Library

Log in to your account

  1. Home
  2. Details for: NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel.
Normal view MARC view ISBD view

NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel. [electronic resource]

By:
  • Xu, Jian
Contributor(s):
  • Ren, Xiaohong
  • Guo, Tao
  • Sun, Xian
  • Chen, Xiaojin
  • Patterson, Laurence H
  • Li, Haiyan
  • Zhang, Jiwen
Producer: 20200205Description: 105034 p. digitalISSN:
  • 1879-0720
Subject(s):
  • Animals
  • Antineoplastic Agents -- therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
  • Calorimetry, Differential Scanning -- methods
  • Cell Line, Tumor
  • Cyclodextrins -- therapeutic use
  • Female
  • HeLa Cells
  • Humans
  • Imidazoles -- therapeutic use
  • Immunologic Factors -- therapeutic use
  • Immunotherapy -- methods
  • Isoindoles -- therapeutic use
  • Magnetic Resonance Spectroscopy -- methods
  • Mice
  • Mice, Inbred BALB C
  • Neoplasms -- drug therapy
  • Paclitaxel -- therapeutic use
  • Small Molecule Libraries -- therapeutic use
  • Solubility -- drug effects
Online resources:
  • Available from publisher's website
In: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences vol. 138
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Cancel rating. Average rating: 0.0 (0 votes)
  • Holdings ( 0 )
  • Title notes ( 1 )
  • Comments ( 0 )
No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

Log in to your account to post a comment.
Browse results Close
Previous
Back to results
Next
  • 1
  • 2
  • 3
  • 4
  • 1 Severe chronic sensory-motor polyneuropathy: coexistence of 3 unrelated etiologies in a type 1 diabetic patient. A case report and review of the literature.
    by Micco, Andrea
  • 2 An intragenic deletion/inversion event in the DMD gene determines a novel exon creation and results in a BMD phenotype.
    by Cagliani, Rachele
  • 3 Novel missense mutation and large deletion of GNE gene in autosomal-recessive inclusion-body myopathy.
    by Del Bo, Roberto
  • 4 Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients.
    by Lunetta, Christian
Close

NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel.

APA

Xu J., Ren X., Guo T., Sun X., Chen X., Patterson L. H., Li H. & Zhang J. (20200205). NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel. : European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Chicago

Xu Jian, Ren Xiaohong, Guo Tao, Sun Xian, Chen Xiaojin, Patterson Laurence H, Li Haiyan and Zhang Jiwen. 20200205. NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel. : European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Harvard

Xu J., Ren X., Guo T., Sun X., Chen X., Patterson L. H., Li H. and Zhang J. (20200205). NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel. : European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

MLA

Xu Jian, Ren Xiaohong, Guo Tao, Sun Xian, Chen Xiaojin, Patterson Laurence H, Li Haiyan and Zhang Jiwen. NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel. : European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 20200205.

  • Print
  • Cite
  • Add to your cart (remove)
  • Save record
    BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
  • More searches
    Search for this title in:
    Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Visit web site